

Medical Equipment & Services

Key data

Price (SEK)*	12.1
Country	Sweden
Bloomberg	ZENI.SS
Reuters	ZENI.TE
Free float	70.9%
Market cap (SEKm)	68
Net debt (current Y/E) (SEKm)	2
No. of shares (m)	5.6
Next event	Q4: 14-Feb

\* Price as at 15:20 CET on 18 November 2019

CEO	Mats Palerius
CFO	Mats Palerius

Company description

Zenitor offers complete system including a thumb EKG and a software backbone used for spontaneous and systematic screening for Atrial Fibrillation, the single most significant indicator for stroke. Zenitor's thumb EKG has been validated by several large scientific studies. Studies show that systematic screening using Zenitor's product is more efficient than the prevailing method, Holter EKG. Several countries are considering national screening programmes for atrial fibrillation but are awaiting additional scientific support. Conclusions from the large Swedish Strokestop study could provide such scientific support in the next couple of years.

Ownership structure

Sonny Norström & co (co owner)	14.9%
Mats Palerius (CEO & co owner)	14.2%
Ydrehall AS	12.4%
Humble Fonder	8.9%
Handelsbanken Fonder	7.3%

Source: Company data

Estimate changes

	19E	20E	21E
Sales	-3.7%	-3.7%	-3.7%
EBITDA	-60.3%	n.m.	-39.3%
EBIT (adj.)	n.m.	n.m.	-81.5%
EPS (adj.)	n.m.	n.m.	n.m.

Source: Danske Bank Equity Research estimates

Analyst(s)

Siri Ladow  
Carolina Elvind

Find our research here:  
<https://research.danskebank.com>

Important disclosures and certifications are contained from page 10 of this report

# Zenitor

## NHS UK deal important step for growth story to materialise

**Q3 was a record quarter for Zenitor, with sales growth of 8%/y/y and positive EBIT for the second time in a row. Although sales growth was slightly lower than our estimates, EBIT continued its positive streak sequentially. The main takeaway in the quarter was the deal signed with the NHS in the UK, a breakthrough step for European expansion. We view the deal as a key driver in this growth story but also as crucial for regaining market trust.**


- Q3 summary.** Sales grew 8% to SEK4.6m (-6% on our estimates), EBIT was positive for the second quarter in a row at SEK65,000 (SEK-1.8m in Q3 18, our estimates SEK-0.8m) with a small but still positive result at SEK7,000 (SEK-1.9m Q3 18, our estimates at SEK-0.9m).
- The CEO expects the increasing growth** in Finland and Sweden to show in next year's numbers, together with continued implementation by the NHS/Bradford Clinical Commissioning Groups (CCGs) in the UK. The CEO's comments rhyme well with our view of accelerated growth in 2020 fuelled by the ongoing UK SAFER study and continued penetration in existing markets and expansion into new ones.
- Zenitor has signed a market opening deal** with the NHS in the UK that applies to, in a first step, five clinical centres within the Bradford CCG. The deal represents 4% of our sales estimates in 2019E but most importantly, it shows that CCGs are willing to implement a new, digitalised care pathway, i.e. Zenitor's thumb EKG. We see a high probability of Zenitor gradually signing several additional contracts with the 191 CCGs of the NHS, supporting top-line growth further.
- The main concern is still cash flow**, which was, as expected, negative at SEK-0.8m, shrinking the cash position to SEK0.4m. However, with current growth prospects to drive operational cash flow and a larger payment by end-2020 from SAFER, cash flow is not a worrying long-term aspect. In the shorter term, we expect cash to be sufficient for current operations and continued investments during 2020, driven by underlying cash flow from licensed revenues and payments from ongoing studies.
- Estimate revisions and valuation.** We adjust our sales estimates for both 2019 and 2020 by -4% due to a somewhat slower than expected increase in utilisation rates in new contracts. We raise the valuation range from SEK32-39 to SEK33-40, mainly due to a revaluation of the peer group.

### Key financials

Year-end Dec (SEK)	2017	2018	2019E	2020E	2021E
Revenues (m)	18	21	22	29	39
Revenues growth	7.3%	12.7%	8.0%	28.0%	35.0%
EBITDA (m)	-3	-2	0	1	2
EBIT adj. (m)	-3	-2	-0	-0	0
EBIT growth	-69.8%	14.5%	97.7%	n.m.	n.m.
Pre-tax profit (m)	-2	-3	-0	-0	0
EPS adj.	-0.46	-0.53	-0.07	-0.03	0.07
DPS	0.00	0.00	0.00	0.00	0.00
Dividend yield					
FCF yield (incl. recurr capex)	-0.5%	-10.1%	-7.3%	1.9%	1.0%
EBIT margin (adj.)	-15.1%	-11.5%	-0.2%	-0.6%	1.1%
Net debt/EBITDA (x)	-1.8	1.3	14.9	0.4	-0.1
ROIC	-37.9%	-21.6%	-0.3%	-1.0%	2.6%
EV/sales (x)	6.0	5.4	3.1	2.4	1.8
EV/EBITDA (adj.) (x)	n.m.	n.m.	n.m.	49.0	31.5
EV/EBIT (x)	n.m.	n.m.	n.m.	49.0	31.5
EV/EBIT (adj.) (x)	n.m.	n.m.	n.m.	n.m.	n.m.
P/E (adj.) (x)	n.m.	n.m.	n.m.	n.m.	n.m.

Source: Company data, Danske Bank Equity Research estimates

### Price performance



	1M	3M	12M	5Y
Absolute	7%	27%	-54%	3%
Rel. local market	3%	13%	-61%	-28%
Rel. EU sector	3%	13%	-61%	-28%

Source: FactSet

## Not for US distribution

## Q3 19 summary

### Positive EBIT streak and positive growth outlook

With a sales growth of 8% y/y and positive EBIT for the second quarter in a row at SEK65,000, Zenicor delivered a record quarter. Although sales growth was somewhat lower than we had expected, the main surprise was EBIT that continued its positive streak sequentially. This along with the deal signed with the NHS in the UK is the main takeaway from the report. We view this as an important step in a European expansion and as a relieving factor for a continued market penetration ahead – a key driver in the growth story but also an important brick for regained market trust.


Table 1. Q3 deviation of actual from estimated results

SEKm	Q3 19A	Q3 19E	Deviation from DB	Q3 18
Sales	4.61	4.91	-6%	4.3
Sales growth	8%	15%	-7	0.3
EBITDA	0.04	-0.82	n.a.	0.0
EBIT	0.06	-0.84	n.a.	-1.8
EBIT margin	1%	neg		neg
PTP	0.01	-0.92	n.a.	-1.9
Net profit	0.01	-0.92	n.a.	0.0
EPS (SEK)	0.00	-0.16	n.a.	0.0
Net debt (cash)	-2.83	-3.20	n.a.	8.1

Source: Company data, Danske Bank Equity Research estimates

The CEO expects the increasing growth in Finland and Sweden together with the implementation by the NHS in the UK to be clearly visible in the numbers during 2020. His comments rhyme well with our view of an acceleration in sales growth in 2020, driven by ripple effects from the UK SAFER study and continued penetration in existing markets and expansion into new ones.

Chart 1. Sales and growth by quarter



Source: Company data, Danske Bank Equity Research estimates

### Market-opening deal with NHS UK supports growth story ahead

At the end of the quarter, Zenicor signed a market-opening agreement with the NHS in the UK, which applies to, in a first step, five clinical centres in the Bradford CCG. The Bradford CCG has 25 clinical centres in total, which we expect to implement digitalised care gradually over the coming years. Encouragingly, the implementation of the first five clinicals seems to have run smoothly in a quick phase, boding well for the process ahead.

Based on similar contracts in Finland, we estimate an around two-year ramp-up from signing to full utilisation, from when the agreement is estimated to generate a revenue of GBP80,000 per year. The deal represents 4% of our sales estimates in 2019E, but most importantly, it shows

### Not for US distribution

that CCGs are willing to implement a new, digitalised care pathway, i.e. Zenicor's thumb EKG. Importantly, we see a high probability of Zenicor gradually signing several additional contracts with the 191 CCGs in the NHS, supporting top-line growth.

We view the deal as particularly important in terms of both an UK and a European market opening and thus as a relieving factor for significant market penetration ahead. We argue a key driver for signing this contract is Zenicor's participation in the NHS-backed SAFER study, validating the product. As there are as much as 191 CCGs in the NHS, we see a high probability of Zenicor gradually signing additional contracts with CCGs, supporting top-line growth.

### *Cash flow and cash position still main concern for the stock*

Cash flow continued to be negative in the quarter at SEK-0.8m, weighted by continued development investments, but supported by a positive change in working capital in terms of a seasonal swingback in receivables. In addition, the cash position of SEK0.4m on the balance sheet is small in absolute and relative terms and has shrunk significantly compared to the SEK11.3m in Q3 last year.

Important to highlight is that the cash flow profile of the unusually big – and therefore unusually important - SAFER-study is back-end loaded, binding working capital while the project is running. With current growth prospects to drive operational cash flow and a larger milestone payment by end-2020 from the SAFER-project, we do not see the negative cash flow as a worrying long-term aspect. Thus, we expect a swingback in working capital and top-line driven positive operational cash flow by end 2020.

Shorter term, we expect the cash position to be sufficient for current operations and continued investments during 2020, thanks to underlying cash flow from licensed revenue through the new PPU-based sales model and payments from several smaller studies with shorter time horizon and thus a closer payment date compared to the SAFER-study. While we expect the cash position to be sufficient, we acknowledge the limited turning space for the company.

### *Estimate revisions*

We adjust our sales estimates for both 2019 and 2020 by -4% due to a somewhat slower than expected increase in utilisation rates in new contracts. The company is currently in the middle of a sales model transition, going from an equipment-based sales model to a pay-per-use sales model, which has a negative effect on sales short term. Longer term, the increase in recurring revenues should, however, warrant a higher valuation multiple, we argue. In addition, fundamentals are in place for a pickup in growth rates in which the deal with the NHS plays an important role – in terms of existing clinical centres in the Bradford CCG but also the high probability of signing several of the other CCGs in the NHS.

Table 2. Zenicor - key figures (1 of 2)

SEKm	Q1 18	Q2 18	Q3 18	Q4 18	2018	Q1 19	Q2 19	Q3 19	Q4 19E
Sales	5.1	5.9	4.3	5.5	20.8	5.7	6.1	4.6	6.0
Sales growth	2%	13%	25%	14%	13%	11%	4%	8%	10%
EBITDA	-0.4	0.2	-1.8	-0.3	-2.3	-0.4	0.3	0.1	0.0
EBIT	-0.4	0.1	-1.8	-0.3	-2.4	-0.4	0.2	0.1	0.0
EBIT-margin	-7.7%	2.3%	-42.6%	-5.5%	-11.5%	-6.7%	4.0%	1.4%	0.3%
PTP	-0.5	0.1	-1.9	-0.4	-2.7	-0.5	0.2	0.0	-0.1
Net profit	-0.5	0.1	-1.9	-0.4	-2.7	-0.5	0.2	0.0	-0.1
EPS (SEK)	-0.11	0.01	-0.33	-0.07	-0.49	-0.09	0.03	0.00	-0.01
Net debt (cash)	-11.4	-8.6	-8.1	-3.1	-3.1	0.4	2.0	2.8	1.9

Source: Company data, Danske Bank Equity Research estimates

### *Not for US distribution*

Table 2: Zenicor - key figures (2 of 2)

SEKm	2019E	2020E	2021E	2022E
Sales	22.5	28.7	38.8	52.4
Sales growth	8%	28%	35%	35%
EBITDA	0.0	1.4	2.2	9.1
EBIT	-0.1	-0.2	0.4	7.1
EBIT-margin	-0.2%	-0.6%	1.1%	13.6%
PTP	-0.4	-0.2	0.4	7.1
Net profit	-0.4	-0.2	0.4	6.4
EPS (SEK)	-0.07	-0.03	0.07	1.13
Net debt (cash)	1.9	0.6	-0.1	-5.4

Source: Danske Bank Equity Research estimates

## Valuation

Zenicor operates in an attractive market with solid structural growth drivers, such as an ageing population and efficiency needs within the healthcare chain. We see a high need for Zenicor's thumb EKG and a high probability of market penetration and good growth. In addition, Zenicor has an established position in terms of scientific support from several studies. The company has accelerated, and should continue to accelerate, its position in the market. We argue that recent large deals add to its validity and that the company's way to market works.

As the company is still in the early stages of the commercial phase, we have based our valuation on estimates two years out in time for a proper view of what sales and margin level the company could deliver.

### Relative multiple valuation and scenario analysis

We have chosen relative multiple valuation as an appropriate valuation method for the Zenicor stock, backed up by risk-weighted DCF. However, as the latter method has an inherited uncertainty in valuation of high-growth companies, we currently use see it as secondary and for comparing purposes.

We value Zenicor on an EV/sales 2021E multiple of 5.3x, implying a discount to the peer group average of 7.2x by 36%. The discount is currently warranted, we argue, as Zenicor is in an earlier stage than most peers are and will have to show accelerated growth rates and achieve scale on the product. Note that Zenicor's larger US peer iRhythm Technologies, who also has a challenger role in its home market, with longer history than Zenicor but a less attractive position in our view, trades on EV/sales 2021E of 4.7x.

Table 3. Healthcare peer group summary - EV/sales

Ticker (FactSet)	Healthcare peers	Price* Ccy (lcl FX)	Ticker (Bloomberg)	Mkt cap (lcl FX)	EV/Sales (x)			
					2018	2019E	2020E	2021E
BIOT-SE	Biotage AB	SEK 122.8	BIOT SS	8,007	8.7	7.3	6.6	5.9
VITR-SE	Vitrolife AB	SEK 184.7	VITR SS	20,049	17.0	13.2	11.5	10.1
SECT.B-SE	Sectra AB Class B	SEK 342.5	SECTB SS	13,136	8.9	8.4	7.6	7.0
AMBU.B-DK	Ambu A/S Class B	DKK 119.95	AMBUB DC	29,393	12.0	11.0	9.2	7.6
BOUL-SE	Boule Diagnostics AB	SEK 63.9	BOUL SS	1,241	2.9	2.7	2.5	2.3
XVIVO-OME	Xvivo Perfusion AB	SEK 162.2	XVIVO SS	4,315	21.9	18.3	13.9	10.1
IRTC-US	iRhythm Technologies, Inc.	USD 69.68	IRTC US	1,841	12.6	8.1	6.1	4.7
	<b>Median (excl. iRhythm &amp; Zenicor)</b>				<b>10.5</b>	<b>9.7</b>	<b>8.4</b>	<b>7.3</b>
	<b>Average (excl. iRhythm &amp; Zenicor)</b>				<b>8.8</b>	<b>7.6</b>	<b>8.6</b>	<b>7.2</b>

\*Prices as at 15:20 CET on 18 November 2019.

Source: FactSet, Danske Bank Equity Research estimates

Our EV/sales multiple of 5.5x implies a value of SEK38. Applying our cautious and optimistic scenarios, we reach a range of SEK33-40. The range is lifted from previously SEK32-39, mainly driven by a small rerating of the peer group. In the longer term and with proven growth capacity,

### Not for US distribution

a valuation in line with peers would be justified given the company's asset-light model, scientific validation of the product and growth above that of peers over the forecast period. Our DCF model indicates a fair value of SEK60 underlining such reasoning, but in light of the inherent uncertainty in the DCF valuations of new high-growth companies, we find the relative multiple valuation more relevant.

Table 4. Scenario valuation summary

	2021E				
2021E	EV/Sales	Mkt cap (SEKm)	Per share (SEK)	Upside	
Bear	4.8	186.2	33.0	173%	
Base	5.3	205.6	36.5	202%	
Bull	5.8	225.0	39.9	230%	
Current share price*		72.0	12.1		

\*Price as at 15:20 CET on 18 November 2019

Source: Danske Bank Equity Research estimates

## *Risks*

Zenicor operates in a competitive industry, with several potential competing products and technologies. The technology is proven and superior to most prevailing methods for atrial fibrillation screening and is supported by several independent studies. Having said this, there is always a risk of new entrants, or existing players developing stronger propositions. There are several global players with strong financial resources, which could increase their marketing efforts to expand their shares in Zenicor's home markets.

The company needs to continue investing in marketing in order to drive volumes, while trimming costs in order to remain competitive. There is a risk increased spending will not result in the expected top-line growth, requiring additional capital injections. In addition, the strain on working capital increases the risk that Zenicor needs additional capital.

A key demand driver for Zenicor is preventive screening for atrial fibrillation. We see a high likelihood of more broad-based screening but these decisions lie outside the company's control. National healthcare systems tend to be slow in adopting new technology and medical professionals can be slow in implementing new technical solutions.

There is a currency risk as Zenicor reports in Swedish krona but sales, to an increasing extent (30% of total sales but 50% of sales growth), are outside of Sweden. Costs are predominantly in Swedish krona. The 30% of revenues not in Swedish krona are mainly in euro and British pounds (with, we believe, minor exposure to Norwegian krone and Swiss francs).

## Company summary

### Sales breakdown, geographical areas

n.a.

### Sales breakdown, divisions

n.a.


### Company information

Zenikor  
Saltmätargatan 8, 113 59 STOCKHOLM  
Sweden  
www.zenikor.se


### Main shareholders

Name	Votes (%)	Capital (%)
Sonny Norström & co (co owner)	14.9%	14.9%
Mats Palerius (CEO & co owner)	14.2%	14.2%
Ydrehall AS	12.4%	12.4%
Humle Fonder	8.9%	8.9%
Handelsbanken Fonder	8.9%	7.3%


### Net sales and EBITDA margin (SEKm)




### EBIT and EBIT-margin (SEKm)



### P/E NTM



### EV/Sales NTM



Source: FactSet, Company data, Danske Bank Equity Research estimates

Not for US distribution

*Summary tables*

<b>INCOME STATEMENT</b>										
<b>Year end Dec, SEKm</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
Net sales	12	15	17	17	18	21	22	29	39	52
Cost of sales & operating costs	-15	-20	-19	-19	-21	-27	-26	-31	-37	-43
<b>EBITDA</b>	<b>-2</b>	<b>-5</b>	<b>-2</b>	<b>-3</b>	<b>-3</b>	<b>-2</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>9</b>
EBITDA, adj.	-2	-5	-2	-3	-3	-2	0	1	2	9
Depreciation	-1	-0	-0	-0	-0	-0	-0	-0	-0	-0
<b>EBITA</b>	<b>-3</b>	<b>-5</b>	<b>-2</b>	<b>-3</b>	<b>-3</b>	<b>-2</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>9</b>
<b>EBIT incl. EO, bef. ass.</b>	<b>-3</b>	<b>-5</b>	<b>-2</b>	<b>-3</b>	<b>-3</b>	<b>-2</b>	<b>-0</b>	<b>-0</b>	<b>0</b>	<b>7</b>
EBIT, adj.	-3	-5	-2	-3	-3	-2	-0	-0	0	7
Financial items, net	0	-0	-0	1	-0	-0	-0	0	0	0
<b>Pre-tax profit</b>	<b>-3</b>	<b>-5</b>	<b>-2</b>	<b>-2</b>	<b>-3</b>	<b>-0</b>	<b>-0</b>	<b>-0</b>	<b>0</b>	<b>7</b>
Taxes								0	-0	-1
<b>Net profit, rep.</b>	<b>-3</b>	<b>-5</b>	<b>-2</b>	<b>-2</b>	<b>-3</b>	<b>-0</b>	<b>-0</b>	<b>0</b>	<b>0</b>	<b>6</b>
Net profit, adj.	-3	-5	-2	-2	-3	-0	-0	-0	0	6
<b>CASH FLOW</b>										
<b>SEKm</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
EBITDA	-2	-5	-2	-3	-3	-2	0	1	2	9
Change in working capital	1	-1	-5	2	-5	-1	4	-1	-3	-3
Net interest paid	-0	-0	-0	1	-0	-0	-0	-0	-0	-0
Taxes paid	-0	-0	-0	-0	-0	-0	-0	0	-0	-1
Other operating cash items										
<b>Cash flow from operations</b>	<b>-2</b>	<b>-6</b>	<b>-7</b>	<b>-0</b>	<b>-7</b>	<b>-1</b>	<b>5</b>	<b>1</b>	<b>6</b>	<b>6</b>
Capex	-0	-0	-0	-0	-4	-3	-4	-0	-0	-0
Div to min										
<b>Free cash flow</b>	<b>-2</b>	<b>-6</b>	<b>-7</b>	<b>-0</b>	<b>-12</b>	<b>-5</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>5</b>
Disposals/(acquisitions)										
<b>Free cash flow to equity</b>	<b>-2</b>	<b>-6</b>	<b>-7</b>	<b>-0</b>	<b>-12</b>	<b>-5</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>5</b>
Dividend paid										
Share buybacks										
New issue common stock	11					18				
Incr./(decr.) in debt						-2				
Minorities & other financing CF	-10	-0	4	-0	2					
<b>Cash flow from financing</b>	<b>11</b>	<b>-0</b>	<b>4</b>	<b>-0</b>	<b>18</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Disc. ops & other										
<b>Incr./(decr.) in cash</b>	<b>10</b>	<b>-6</b>	<b>-3</b>	<b>-1</b>	<b>6</b>	<b>-5</b>	<b>1</b>	<b>1</b>	<b>5</b>	<b>5</b>
<b>BALANCE SHEET</b>										
<b>SEKm</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
Cash & cash equivalents	10	4	1	0	6	1	3	3	9	9
Inventory	2	1	3	4	4	4	5	6	8	8
Trade receivables	2	3	4	4	4	5	6	8	11	11
Other current assets	1	1	2	3	7	8	4	4	5	5
Goodwill	1									
Other intangible assets						4	7	9	8	6
Fixed tangible assets		0	0	0	0	0	0	0	1	1
Associated companies	0	0	0	0	0	0	0	0	0	0
Other non-current assets	0	0	0	0	0	0	0	0	0	0
<b>Total assets</b>	<b>15</b>	<b>9</b>	<b>11</b>	<b>12</b>	<b>26</b>	<b>26</b>	<b>27</b>	<b>30</b>	<b>40</b>	<b>40</b>
<b>Shareholders' equity</b>	<b>12</b>	<b>7</b>	<b>5</b>	<b>3</b>	<b>18</b>	<b>17</b>	<b>17</b>	<b>18</b>	<b>24</b>	<b>24</b>
Of which minority interests										
Current liabilities	3	2	3	4	5	5	7	9	13	13
Interest-bearing debt	1	0	3	5	3	3	3	3	3	3
Pension liabilities										
Oth non-curr. liabilities										
<b>Total liabilities</b>	<b>4</b>	<b>3</b>	<b>6</b>	<b>9</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>12</b>	<b>16</b>	<b>16</b>
<b>Total liabilities and equity</b>	<b>15</b>	<b>9</b>	<b>11</b>	<b>12</b>	<b>26</b>	<b>26</b>	<b>27</b>	<b>30</b>	<b>40</b>	<b>40</b>
Net debt	-9	-3	2	5	-3	2	1	-0	-5	-5

Source: Company data, Danske Bank Equity Research estimates

*Summary tables*

<b>PER SHARE DATA</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
No. of shares, fully diluted (y.e.) (m)			4.5	4.5	4.6	5.6	5.6	5.6	5.6	5.6
No. of shares, fully diluted (avg.) (m)			4.5	4.5	4.5	5.1	5.6	5.6	5.6	5.6
EPS (SEK)			-1.12	-0.38	-0.46	-0.53	-0.07	-0.03	0.07	1.13
EPS adj. (SEK)			-1.12	-0.38	-0.46	-0.53	-0.07	-0.03	0.07	1.13
DPS (SEK)			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37
CFFO/share (SEK)			-1.4	-1.6	-0.1	-1.4	-0.3	0.9	0.2	1.0
Book value/share (SEK)			1.51	1.11	0.61	3.14	3.07	3.04	3.11	4.24
<b>MARGINS AND GROWTH</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
EBITDA margin			-17.6%	-32.7%	-9.3%	-14.6%	-11.0%	0.6%	4.9%	17.3%
EBITA margin			-21.8%	-32.9%	-9.5%	-15.1%	-11.5%	0.2%	4.9%	17.3%
EBIT margin			-21.8%	-32.9%	-9.5%	-15.1%	-11.5%	-0.2%	1.1%	13.6%
EBIT adj margin			-21.8%	-32.9%	-9.5%	-15.1%	-11.5%	-0.2%	1.1%	13.6%
Sales growth				22.0%	14.2%	7.3%	12.7%	8.0%	28.0%	35.0%
EBITDA growth				n.m.	67.6%	-69.3%	14.9%	n.m.	53.9%	n.m.
EBITA growth				-84.4%	66.8%	-69.8%	14.5%	n.m.	53.9%	n.m.
EPS adj growth					65.9%	-21.1%	-13.9%	86.7%	58.6%	n.m.
<b>PROFITABILITY</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
ROIC (after tax, incl. GW, adj.)			-199.8%	-164.2%	-31.3%	-37.9%	-21.6%	-0.3%	2.6%	42.8%
ROIC (after tax, excl. GW, adj.)			-246.1%	-179.2%	-31.3%	-37.9%	-21.6%	-0.3%	2.6%	42.8%
ROE (adj.)			-47.9%	-54.2%	-29.2%	-54.1%	-26.3%	-2.3%	2.1%	30.7%
ROIC (adj.) - WACC			-208.2%	-172.6%	-39.8%	-46.4%	-30.1%	-8.8%	-5.8%	34.4%
<b>MARKET VALUE</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
Share price (SEK)		10.2	9.20	18.9	23.0	20.4	12.1	12.1	12.1	12.1
No. shares reduced by buybacks (m)			4.5	4.5	4.6	5.6	5.6	5.6	5.6	5.6
<b>Mkt cap used in EV (m)</b>			<b>41</b>	<b>84</b>	<b>107</b>	<b>115</b>	<b>68</b>	<b>68</b>	<b>68</b>	<b>68</b>
Net debt, year-end (m)		-9	-3	2	5	-3	2	1	-0	-5
MV of min/ass and oth (m)		-0	-0	-0	-0	-0	-0	-0	-0	-0
<b>Enterprise value (m)</b>			<b>38</b>	<b>86</b>	<b>111</b>	<b>112</b>	<b>70</b>	<b>69</b>	<b>68</b>	<b>63</b>
<b>VALUATION</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
EV/sales (x)			2.5	5.0	6.0	5.4	3.1	2.4	1.8	1.2
EV/EBITDA (x)			n.m.	n.m.	n.m.	n.m.	n.m.	49.0	31.5	6.9
EV/EBITA (x)			n.m.	n.m.	n.m.	n.m.	n.m.	49.0	31.5	6.9
EV/EBIT (x)			n.m.	8.8						
P/E (reported) (x)			n.m.	10.7						
P/E (adj.) (x)			n.m.	10.7						
P/BV (x)			6.10	17.1	37.6	6.49	3.94	3.98	3.89	2.86
EV/invested capital (x)										
Dividend yield										3.07%
Total yield (incl. buybacks)										3.07%
FCFE-yield			-15.04%	-8.27%	-0.46%	-10.06%	-7.27%	1.93%	0.99%	7.77%
<b>FINANCIAL RATIOS</b>	<b>2013</b>	<b>2014</b>	<b>2015</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
Net debt/EBITDA (x)		4.1	0.6	-1.5	-1.8	1.3	14.9	0.4	-0.1	-0.6
Net debt/equity (x), year-end		-0.8	-0.5	0.5	1.7	-0.2	0.1	0.0	-0.0	-0.2
Dividend payout ratio			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	33.0%
Interest coverage (x)		-22.7	n.m.	-28.0	-6.0					
Cash conversion (FCF/net profit)		n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	183.1%	83.4%
Capex/sales		0.4%	0.5%	0.3%	0.7%	19.8%	15.5%	13.2%	0.7%	0.7%
NWC/sales		17.3%	21.4%	40.6%	39.8%	49.1%	51.1%	27.0%	23.0%	22.0%
<b>QUARTERLY P&amp;L</b>			<b>Q1 18</b>	<b>Q2 18</b>	<b>Q3 18</b>	<b>Q4 18</b>	<b>Q1 19</b>	<b>Q2 19</b>	<b>Q3 19</b>	<b>Q4 19E</b>
Sales (m)			5	6	4	5	6	6	5	6
EBITDA (m)			-0	0	-2	-0	-0	0	0	0
EBIT before non-recurring items (m)			-0	0	-2	-0	-0	0	0	0
Net profit (adj.) (m)			-1	0	-2	-0	-1	0	0	-0
EPS (adj.) (SEK)			-2.87	0.44	-10.33	-0.55	-0.43	0.14	0.01	-0.05
EBITDA margin			-7.7%	2.3%	-42.6%	-3.9%	-6.7%	4.0%	1.4%	3.3%
EBIT margin (adj.)			-7.7%	2.3%	-42.6%	-5.5%	-6.7%	4.0%	1.4%	0.3%

Source: Company data, Danske Bank Equity Research estimates

## Disclosures

This commissioned research report has been prepared by Equity Research, a division of Danske Bank A/S ('Danske Bank'). The authors of this research report are Siri Ladow and Carolina Elvind.

This commissioned research report should be considered marketing material, as it has been requested and paid for by Zenicor and has therefore not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, the report is still subject to prohibition on dealing ahead of the dissemination of the report.

### *Analyst certification*

Each research analyst responsible for the content of this commissioned research report certifies that the views expressed in the research report accurately reflect the research analyst's personal view about the financial instruments and issuers covered by the research report.

### *Regulation*

Danske Bank is authorised and subject to regulation by the Danish Financial Supervisory Authority and is subject to the rules and regulation of the relevant regulators in all other jurisdictions where it conducts business. Danske Bank is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority (UK). Details on the extent of the regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from Danske Bank on request.

Danske Bank's commissioned research reports are prepared in accordance with the recommendations of the Danish Securities Dealers Association.

### *Conflicts of interest*

Danske Bank has established procedures to prevent conflicts of interest and to ensure the provision of high-quality research based on research objectivity and independence from outside influences. These procedures are documented in Danske Bank's research policies. Employees within Danske Bank's Research Departments have been instructed that any request that might impair the objectivity of research and independence from outside influence of research shall be referred to Research Management and the Compliance Department. Danske Bank's Research Departments are organised independently from and do not report to other business areas within Danske Bank.

Research analysts are remunerated in part based on the overall profitability of Danske Bank, which includes investment banking revenues, but do not receive bonuses or other remuneration linked to specific corporate finance or debt capital transactions.

Danske Bank, its affiliates, subsidiaries and staff may perform services for or solicit business from Zenicor and may hold long or short positions in, or otherwise be interested in, the financial instruments mentioned in this research report. The Equity and Corporate Bonds analysts of Danske Bank and undertakings with which the Equity and Corporate Bonds analysts have close links are, however, not permitted to invest in financial instruments that are covered by the relevant Equity or Corporate Bonds analyst or the research sector to which the analyst is linked.

Danske Bank, its affiliates and subsidiaries are engaged in commercial banking, securities underwriting, dealing, trading, brokerage, investment management, investment banking, custody and other financial services activities, may be a lender to Zenicor and have whatever rights as are available to a creditor under applicable law and the applicable loan and credit agreements. At any time, Danske Bank, its affiliates and subsidiaries may have credit or other information regarding Zenicor that is not available to or may not be used by the personnel responsible for the preparation of this report, which might affect the analysis and opinions expressed in this research report.

Danske Bank is a market maker and a liquidity provider and may hold positions in the financial instruments of the issuer(s) mentioned in this research report.

Parts of this research report have been disclosed to Zenicor for factual check.

As an investment bank, Danske Bank, its affiliates and subsidiaries provide a variety of financial services, including investment banking services. It is possible that Danske Bank and/or its affiliates and/or its subsidiaries might seek to become engaged to provide such services to Zenicor in the next three months.

### *Financial models and/or methodology used in this research report*

Investment views and opinions in this research report are formed on the basis of a combined selection of discounted cash flow analysis, industry knowledge, peer group analysis and company-specific and market technical elements (events affecting both the financial and operational profile of the company). Forecasting of company sales and earnings is based on segmented bottom-up models using subjective views of relevant future market developments. In addition, the expected macroeconomic environment is taken into account. The output is aggregated into models for group profit and loss, balance sheets and cash flow estimates – all taking into account the recent development in historical research reports.

More information about the valuation and/or methodology and the underlying assumptions is accessible via [www.danskebank.com/equityresearch](http://www.danskebank.com/equityresearch).

### *Risk warning*

Major risks connected with investment views or opinions in this research report, including a sensitivity analysis of relevant assumptions, are stated throughout the text.

### *Expected updates*

This research product will be updated on a semi-annual basis as a minimum.

### *Completion and first dissemination*

The completion date and time in this research report mean the date and time when the author hands over the final version of the research report to Danske Bank's editing function for legal review and editing.

The date and time of first dissemination mean the date and estimated time of the first dissemination of this research report. The estimated time may deviate up to 15 minutes from the effective dissemination time due to technical limitations.

See the back page of this research report for the date and time of first dissemination.

### *Recommendation structure*

This report does not have a recommendation or target price but it does include a valuation discussion and a suggested valuation range.

## Not for US distribution

*Validity time period*

This communication as well as previous communications referred to below are valid until the earlier of (a) dissemination of a superseding communication by the author, or (b) significant changes in circumstances following its dissemination, including events relating to the market or the issuer, which can influence the price of the issuer or financial instrument.

*Investment recommendations disseminated in the preceding 12-month period*

Not relevant for this publication as no recommendations are connected to the report.

## *Disclaimer*

This commissioned research has been prepared by Equity Research (a division of Danske Bank A/S). It is provided for informational purposes only and should not be considered investment advice. It does not constitute or form part of, and shall under no circumstances be considered as, an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instruments (i.e. financial instruments mentioned herein or other financial instruments of any issuer mentioned herein and/or options, warrants, rights or other interests with respect to any such financial instruments) ("Relevant Financial Instruments").

The research report has been prepared independently of outside influence and solely on the basis of publicly available information that Danske Bank considers to be reliable. While reasonable care has been taken to ensure that its contents are not untrue or misleading, no representation is made as to its accuracy or completeness and Danske Bank, its affiliates and subsidiaries accept no liability whatsoever for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this research report.

The opinions expressed herein are the opinions of the research analysts responsible for the research report and reflect their judgement as of the date hereof. These opinions are subject to change and Danske Bank does not undertake to notify any recipient of this research report of any such change nor of any other changes related to the information provided in the research report.

This research report is not intended for, and may not be redistributed to, retail customers in the United Kingdom and may under no circumstances be distributed in the United States.

This research report is protected by copyright and is intended solely for the designated addressee. It may not be reproduced or distributed, in whole or in part, by any recipient for any purpose without Danske Bank's prior written consent.

Report completed: 18 November 2019 at 15:40 CET

Report disseminated: 18 November 2019 at 19:20 CET

*Not for US distribution*